KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Inventory (2018 - 2025)

Takeda Pharmaceutical (TAK) has 8 years of Inventory data on record, last reported at $8.0 billion in Q1 2025.

  • For Q1 2025, Inventory fell 2.26% year-over-year to $8.0 billion; the TTM value through Mar 2025 reached $8.0 billion, down 2.26%, while the annual FY2025 figure was $8.0 billion, 4.74% down from the prior year.
  • Inventory reached $8.0 billion in Q1 2025 per TAK's latest filing, down from $8.2 billion in the prior quarter.
  • Across five years, Inventory topped out at $8.2 billion in Q1 2024 and bottomed at $7.1 billion in Q1 2021.
  • Average Inventory over 5 years is $7.6 billion, with a median of $7.5 billion recorded in 2023.
  • Peak YoY movement for Inventory: increased 9.47% in 2024, then dropped 2.26% in 2025.
  • A 5-year view of Inventory shows it stood at $7.1 billion in 2021, then rose by 3.08% to $7.3 billion in 2022, then rose by 1.58% to $7.5 billion in 2023, then increased by 9.47% to $8.2 billion in 2024, then dropped by 2.26% to $8.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $8.0 billion in Q1 2025, $8.2 billion in Q1 2024, and $7.5 billion in Q1 2023.